drug
gabapentin enacarbil ER
Marketedupdated 5mo agoby Azurity Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying gabapentin enacarbil ER
- phase4A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
- phase4Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
- phase4An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 10, 2026
36 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 10, 2029formulationUS 87957252.7y
- Jun 10, 2029formulationUS 87957252.7y
- Nov 10, 2026compositionUS 802627936d
- Nov 10, 2026compositionUS 802627936d
- Apr 11, 2026method-of-use (U-1231)US 8114909
- Apr 11, 2026method-of-use (U-1231)US 8114909
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that